About

About Pharmasaga Co. Ltd. Pharmasaga Co. Ltd. (https://www.pharmasaga.com/en/index.aspx), is a drug discovery and development company. It aims to develop novel anti-diabetic small-molecule drugs that can treat and reverse diabetes. Pharamsaga pioneered to study function and mechanism of Pdia4, a master gene that controls β-cell pathogenesis and, in turn, diabetes. Using a rational drug design strategy, combining molecular docking, Pdia4 bioassay, and chemical synthesis, PS1, a Pdia4-based drug candidate, was developed for diabetes. This novel drug precisely targets diabetes and has the potential to become the world's first curative treatment for diabetes. After receving IND approvals from the USFDA and Taiwanese FDA, PS1 is now on human trials for type 2 diabetes, followed by human trials for type 1 diabetes and pancreatic cancer. Preliminary data showed that PS1 had high safety and great efficacy in decreased blood glucose. Additionally, Orphan Drug Designation (ODD) of PS1 was applied to USFDA.